- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
National Pharmaceutical Council Appoints Dr. Sharon Phares as Chief Scientific Officer
The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of good evidence, science and medical innovation, announced the appointment of Sharon Phares, PhD, MPH, as chief scientific officer.
Press Release
Washington, D.C. – January 4, 2022 – The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of good evidence, science and medical innovation, today announced the appointment of Sharon Phares, PhD, MPH, as Chief Scientific Officer. Dr. Phares will replace Robert W. Dubois, MD, PhD, who is retiring from NPC at the end of February 2022.
Dr. Phares, who assumes the role today, will direct NPC’s research strategy and oversee the organization’s research on policy issues, including demystifying pharmaceutical pricing perceptions, addressing challenges of health technology assessments, and examining underlying issues of patient access and affordability.
Prior to joining NPC, Dr. Phares was the Senior Vice President of Research at Pharmaceutical Strategies Group (PSG), an EPIC company, where she developed and managed all research efforts, transforming research objectives into study designs, analytic plans, and survey tools, and translating research findings into actionable information to support both internal and external clients. She also serves as an Adjunct Assistant Professor of Medicine at the Washington University School of Medicine in St. Louis.
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
AMGA Releases Population Health Framework to Improve ASCVD Secondary Prevention
June 18th 2025Proven interventions to improve care, address disparities, and support lipid management are woven throughout AMGA Foundation's new framework to guide population health–based secondary prevention strategies for atherosclerotic cardiovascular disease (ASCVD).
Read More
